Selection of an immunogenic peptide mimic of the capsular polysaccharide of Neisseria meningitidis serogroup A using a peptide display library

Vaccine

Volumn 18, Issue 13, 2000, Pages 1253-1263

  Grothaus, Matthew C ^a   Srivastava, Neeti ^a   Smithson, S Louise ^a   Kieber Emmons, Thomas ^b   Williams, Derrick B ^c   Carlone, George M ^c   Westerink, M A Julie ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

Author keywords

Meningococcal group A vaccine; Peptide mimicry; Phage display

Indexed keywords

BACTERIAL POLYSACCHARIDE; IDIOTYPIC ANTIBODY; MENINGOCOCCUS VACCINE; MONOCLONAL ANTIBODY;

ANIMAL MODEL; ANTIBODY SPECIFICITY; ARTICLE; BACTERIAL MENINGITIS; CENTRAL NERVOUS SYSTEM INFECTION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NEISSERIA MENINGITIDIS; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; VACCINATION;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; BACTERIAL VACCINES; BACTERIOPHAGES; BLOOD BACTERICIDAL ACTIVITY; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNIZATION, SECONDARY; MENINGOCOCCAL VACCINES; MICE; MICE, INBRED BALB C; MOLECULAR MIMICRY; MOLECULAR SEQUENCE DATA; NEISSERIA MENINGITIDIS; PEPTIDE LIBRARY; PEPTIDES; POLYSACCHARIDES, BACTERIAL;

EID: 0033986926     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00390-4     Document Type: Article

References (60)

1. Greenwood B.M., Bradley A.K., Smith A.W., Wall R.A. Mortality from meningococcal disease during anepidemic in The Gambia, West Africa. Trans. R. Soc. Trop. Med. Hyg. 81:1987;536-538.
2. Patterson K.D., Hartwig G.W. Cerebrospinal meningitis in West Africa and Sudan in the twentieth century. 1984;1-76 Crossroads Press, Los Angeles.
3. Kabat E.A., Miller C.P., Kaiser H., Foster A.Z. Chemical studies on bacterial agglutination. VII. A quantitative study on the type specific and group specific antibodies in antimeningococcal sera of various species and their relation to mouse protection. J. Exp. Med. 81:1945;1-8.
4. Binkin N., Band J. Epidemic of meningococcal meningitis in Bamako, Mali: epidemiological features and analysis of vaccine efficacy. Lancet. 2:1982;315-317.
5. Bosmans E., Vimont-Vicary P., Adre F.E., Crooy P.J., Roelants P., Vandepitte J. Protective efficacy of a bivalent (A+C) meningococcal vaccine during a cerebrospinal meningitis epidemic in Rwanda. Ann. Soc. Belg. Med. Trop. 60:1980;297-306.
6. Erwa H.H., Haseeb M.A., Idris A.A., Lapeyssonnie L., Sanborn W.R., Sippel J.E. A serogroup A meningococcal polysaccharide vaccine. Studies in the Sudan to combat cerebrospinal meningitis caused by Neisseria meningitidis group A. Bull. WHO. 49:1973;301-305.
7. Ettori D, Saliou P, Renaudet J, Ph S. Le vaccin antimeningococcique polysaccharidique du type A: premeir essais controles en Afrique de L'Ouest, Med. Trop. 37:225-230.
8. Greenwood B.M., Wali S.S. Control of meningococcal infection in the African meningitis belt by selective vaccination. Lancet. 1:1980;729-732.
9. Greenwood B.M., Smith A.W., Hassen-King M., et al. The efficacy of meningococcal polysaccharide vaccine in preventing group A meningococcal disease in The Gambia, West Africa. Trans. R. Soc. Trop. Med. Hyg. 80:1986;106-107.
10. Carlone G.M., Frasch C.E., Siber G.R., Quataert S., Gheesling L.L., Turner S.H., Plikaytis B.D., Helsel L.O., DeWitt W.E., Bibb W.F. Multicenter comparison of levels of antibody to the Neisseria meningitides group A capsular polysaccharide measured by using an enzyme-linked immunosorbent assay. J. Clin. Microbiol. 30:1992;154-159.
11. Mohammed I., Zaruba K. Control of epidemic meningococcal meningitis by mass vaccination. Lancet. 2:1981;80-82.
12. Wahdan M.H., Sallam S.A., Hassan M.N. A second controlled field trial of a serogroup A meningococcal polysaccharide vaccine in Alexandria. Bull. WHO. 55:1977;645-651.
13. Wahdan M.H., Rizk F., El-Akkad A.M., et al. A controlled trial of a serogroup A meningococcal polysaccharide vaccine. Bull. WHO. 48:1973;667-673.
14. Reingold A.L., Broome C.V., Hightower A.W., et al. Age-specific differences in duration of clinical protection of clinical protection after vaccination with meningococcal polysaccharide A vaccine. Lancet. 2:1985;114-118.
15. Greenwood B.M., Whittle H.C., Bradley A.K., Fayet M.T., Gilles H.M. The duration of the antibody response to meningococcal vaccination in an African village. Trans. R. Soc. Trop. Med. Hyg. 75:1980;756-760.
16. Ceesay SJ, Allen SJ, Menon A et al. Decline in meningococcal antibody levels in African children 5 years after vaccination and the lack of an effect of booster immunization. J Infect Dis 1993;167:1212-1216.
17. Adams W.G., Deaver K.A., Cochi S.L., Plikaytis B.D., Zell E.R., Broome C.V., Wenger J.D. Decline of childhood Haemophilus influenzae type b disease in the Hib vaccine era. JAMA. 269:1993;221-226.
18. Broadhurst L.E., Erickson R.L., Kelly P.W. Decrease in invasive Haemophilus influenzae diseases in US Army children, 1984-1991. JAMA. 269:1991;227-231.
19. Anderson E.L., Bowers T., Mink C.M., Kennedy D.J., Belshe R.B., Harakeh H., et al. Safety and immunogenicity of meningococcal A and C polysaccharide conjugate vaccine in adults. Infect. Immun. 62:1994;3391-3395.
20. Twumasi P.A. Jr, Kumah S., Leach A., Dempsey T.J.D., Ceesay S.J., Todd J., et al. A trial of a group A plus group C meningococcal polysaccharide-protein conjugate vaccine in African infants. J. Infect. Dis. 171:1995;632-638.
21. Leach A., Twumasi P.A., Kumah S., Banya W.S., Jaffar S., Forrest B.D., et al. Induction of immunologic memory in Gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide-protein conjugate vaccine. J. Infect. Dis. 175:1997;200-204.
22. MacDonald N.E., Halperin S.A., Law B.J., Forrest B., Danzig L.E., Granoff D.M. Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial. JAMA. 280:1998;1685-1689.
23. Fairley C.K., Begg N., Borrow R., Fox A.J., Jones D.M., Cartwright K. Conjugate meningococcal serogroup A and C vaccine: reactogenicity and immunogenicity in United Kingdom infants. J. Infect. Dis. 174:1996;1360-1363.
24. Lieberman J.M., Chiu S.S., Wong V.K., Partidge S., Chang S.J., Chiu C.Y., et al. Safety and immunogenicity of a serogroups A/C Neisseria meningitidis oligosaccharide-protein conjugate vaccine in young children. A randomized controlled trial. JAMS. 275:1996;1499-1503.
25. Seppala I., Pelkonen J., Makela O. Isotypes of antibodies induced by plain dextran or a dextran-protein conjugate. Eur. J. Immunol. 15:1985;827-833.
26. Seppala I., Sarvas H., Makela O., Mattila P., Eskola J., Kayhty H. Human antibody responses to two conjugate vaccines of Haemophilus influenzae type B saccharides and diphtheria toxin. Scand. J. Immunol. 28:1988;471-479.
27. Peeters C.C., Tenbergen-Meekes A.M., Poolman J.T., Beurret M., Zegers B.J., Rijkers G.T. Effect of carrier priming on immunogenicity of saccharide-protein conjugate vaccines. Infect. Immun. 59:1991;3504-3510.
28. Westerink M.A.J., Campagnari A.A., Wirth M.A., Apicella M.A. Development and characterization of an anti-idiotype antibody to the capsular polysaccharide of Neisseria meningitidis serogroup C. Infect. Immun. 56:1988;1120-1127.
29. Westerink M.A.J., Giardina P.C., Campagnari A.A., Apicella M.A. The thymus dependent nature of the murine antibody response to a monoclonal anti-idiotypic antibody to the Neisseria meningitidis serogroup C capsular polysaccharide. Microb. Pathog. 8:1990;411-419.
30. Westerink M.A.J., Giardina P.C. Anti-idiotype induced protection against Neisseria meningitidis serogroup C bacteremia. Microb. Pathog. 12:1992;19-26.
31. Westerink M.A.J., Giardina P.C., Apicella M.A., Kieber-Emmons T. Peptide mimicry of the meningococcal group C capsular polysaccharide. Proc. Natl. Acad. Sci. USA. 92:1995;4021-4025.
32. Houghton R.A., Pinilla C., Blondelle S.E., Appel J.R., Dooley C.T., Cuervo J.H. Generation and use of syntheteic peptide combinatorial libraries for basic research and drug discovery. Nature. 354:1991;84-86.
33. Felici F., Castagnoli L., Musecchio A., Jappelli R., Cesareni G. Selection of antibody ligands from a large library of oligopeptides expressed on a multivalent exposition vector. J. Mol. Biol. 222:1991;301-310.
34. Devlin J.J., Panganiban L.C., Devlin P.E. Random peptide libraries: a source of specific protein binding molecules. Science. 249:1990;404-406.
35. Cwirla S.E., Peters E.A., Barret R.W., Dower W.J. Peptides on phage: a vast library of peptides for identifying ligands. Proc. Natl. Acad. Sci. USA. 87:1990;6378-6382.
36. Scott J.K., Smith G.P. Searching for peptide ligands with an epitope library. Science. 249:1990;386-390.
37. O'Neil K.T., Hoess R.H., Jackson S.A., Ramachandran N.S., Mousa S.A., DeGrado W.F. Identification of novel peptide antagonists for GP IIb/IIIa from a conformationally constrained phage peptide library. Proteins. 14:1992;509-515.
38. Oldenburg K.R., Loganathan D., Goldstein I.J., Schultz P.G., Gallop M.A. Peptide ligands for a sugar-binding protein isolated from a random peptide library. Proc. Natl. Acad. Sci. USA. 89:1992;5393-5397.
39. Hoess R., Brinkmann U., Handel T., Pastan I. Identification of a peptide which binds to the carbohydrate-specific monoclonal antibody B3. Gene. 128:1993;43-49.
40. Kennett R. Cell fusion. Methods Enzymol. 58:1993;345-359.
41. Smith G.P., Scott J.K. Libraries of peptides and protein displayed on filamentous phage. Meth. Enzymol. 217:1993;228-257.
42. Parmley S.F., Smith G.P. Antibody-selectable filamentous fd phage vectors: affinity purification of target genes. Gene. 73:1988;305-318.
43. Valadon P., Nussbaum G., Boyd L.F., Margulies D.H., Scharff M.D. Peptide libraries define the fine specificity of anti-polysaccharide antibodies to Cryptococcus neoformans. J. Mol. Biol. 261:1996;11-22.
44. Sambrook J., Fritsch E.F., Maniatis T. Molecular cloning: a laboratory manual. 2nd ed. 1989;Cold Harbor Spring Press, New York. [Extraction and Purification of RNA].
45. Lowell G.H., Smith L.F., Seid R.C., Zollinger W.D. Peptides bound to proteosomes via hydrophobic feet become highly immunogenic without adjuvants. J. Exp. Med. 167:1988;658-663.
46. Zollinger W.D., Mandrell R.E., Griffiss J.M., Altieri P., Berman S. Complex of meningococcal group B polysaccharide and type 2 outer membrane protein immunogens in man. J. Clin. Invest. 63:1979;836-848.
47. Monfardini C., Kieber-Emmons T., Vonfeldt J.M., O'Malley B., Rosenbaum H., Godillot A.P., et al. Recombinant antibodies in bioactive peptide design. J. Biol. Chem. 270:1995;6628-6638.
48. Barrett R.W., Cwirla S.E., Ackerman M.S., Olson A.M., Peters E.A., Dower W.J. Selective enrichment and characterization of high affinity ligands from collections of random peptides on filamentous phage. Anal. Biochem. 204:1992;357-364.
49. Granoff D.M., Holmes S.J., Osterholm M.T., McHugh J.E., Lucas A.H., Anderson E.L., et al. Induction of immunologic memory in infants primed with Haemophilus influenzae type b conjugate vaccines. J. Infect. Dis. 168:1993;663-671.
50. Anderson E.L., Kennedy D.J., Geldmacher K.M., Donnelly J., Mendelman P.M. Immunogenicity of heptavalent pneumococcal conjugate vaccine in infants. J. Pediatr. 128:1996;649-653.
51. Phalipon A., Folgori A., Arondel J., Sgaramella G., Fortugno P., Cortese R., et al. Induction of anti-carbohydrate antibodies by phage library-selected peptide mimics. Eur. J. Immunol. 27:1997;2620-2625.
52. Harris S.L., Craig L., Mehroke J.S., Rashed M., Zwick M.B., Kenar K., et al. Exploring the basis of peptide-carbohydrate crossreactivity: evidence for discrimination by peptides between closely related anti-carbohydrate antibodies. Proc. Natl. Acad. Sci. USA. 94:1997;2454-2459.
53. Bona C.A., Kohler H. Anti-idiotypic antibodies and internal images. Venter J.C., Fraser C.M., Linstrom J. Monoclonal and anti-Idiotypic antibodies: probes for receptor structure and function. Receptor biochemistry and methodology series. 1984;141-149 Alan R. Liss, New York.
54. Dixon F., Maurer P. Immunologic unresponsiveness induced by protein antigens. J. Exp. Med. 101:1955;245-257.
55. Weber G., Kolsch E. Transfer of low zone tolerance to normal syngeneic mice by theta-positive cells. Eur. J. Immunol. 3:1973;767-772.
56. Parish C.R., Liew F.Y. Immune response to chemically modified flagellin. 3. Enhanced cell-mediated immunity during high and low zone antibody tolerance to flagellin. J. Exp. Med. 135:1972;298-311.
57. Eynon E.E., Parker D.C. Small B cells as antigen-presenting cells in the induction of tolerance to soluble protein antigens. J. Exp. Med. 175:1992;131-138.
58. Insel R.A., Adderson E.E., Carroll W.L. The repertoire of human antibody to the Haemophilus influenzae type b capsular polysaccharide. Int. Rev. Immunol. 9:1992;25-43.
59. Kabat E.A. Antibody complementarity and antibody structure. J. Immunol. 141:1988;S25-S36.
60. Pincus S.H., Smith M.J., Jennings H.J., Burritt J.B., Glee P.M. Peptides that mimic the group B streptococcal type III capsular polysaccharide antigen. J. Immunol. 160:1998;293-298.